United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Pfizer (PFE) and BioNTech (BNTX) report 100% efficacy for their COVID-19 vaccine in teenagers aged 12 to 15.

Pfizer (PFE)/BioNTech COVID-19 Vaccine 100% Effective in Teens

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in Phase 3 study through March 13. Data showed that the vaccine, BNT162b2, was 91.3% effective against COVID-19 infection, measured seven days through up to six months after the second dose.

Pfizer-BioNTech COVID-19 Shot Safe, Effective Through Six Months After Second Dose

AbbVie

AbbVie stock tumbled in mid-March after the Food and Drug Administration requested additional information before considering new approvals for its potential blockbuster drug, Rinvoq. The post Is It Time To Buy AbbVie Stock — Or Will Pfizer's Bad News Continue To Hurt?

Is It Time To Buy AbbVie Stock — Or Will Pfizer's Bad News Continue To Hurt?

Pfizer Inc. and German partner BioNTech SE said Thursday a study of COVID-19 patients six months after receiving a second dose of their vaccine BNT162b2 confirmed its high efficacy and lack of serious safety concerns. The companies said an analysis of 927 confirmed symptomatic cases of COVID-19 showed the vaccine had a 91.3% efficacy against the illness, measured seven days through up to six months after the second dose.

Pfizer, BioNTech say study of COVID-19 patients six months after second vaccine dose proved it is safe and effective

New study of Pfizer vaccine finds it's effective against South African variant

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Post Hoc Analysis for landmark study.

Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

Updated results from Pfizer's late-stage study of its coronavirus vaccine show the two-dose shot's overwhelming protection is holding up six months after the second dose. The study has tallied 927 symptomatic cases of COVID-19 among just over 46,000 trial volunteers. People who got placebo shots accounted for 850 of those cases compared to 77 illnesses among those who received the vaccine, which was developed by Pfizer and BioNTech. That translates to 91.3% efficacy, the companies said in a statement on Thursday.

Pfizer's COVID-19 shot remains highly protective against the coronavirus, longer-term data shows

Danny Hendrikse, Pfizer's vice president for global supply, says European Union red tape has caused “a significant administrative burden.”

Pfizer warns EU bureaucracy is holding back worldwide vaccine efforts

It's too soon to know for sure, but Pfizer could be moving in a good direction.

Pfizer's Decision to Develop mRNA Vaccines on Its Own: Brilliant or Boneheaded?

The companies plan to apply for emergency use authorization in adolescents in the coming weeks.

Pfizer and BioNTech's COVID-19 Vaccine Produces 100% Protection in Kids

Pfizer Inc. (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) announced positive results Wednesday from a late-stage study of the COVID-19 vaccine BNT162b2 in adolescents. The Pfizer Analyst: Cantor Fitzgerald analyst Louise Chen maintained an Overweight rating on Pfizer with a $53 price target.

Pfizer's Late-Stage COVID-19 Vaccine Data In Adolescents Reinforces Bull Case, Analyst Says

The company will send its new findings to the FDA.

Pfizer says its COVID-19 vaccine is 100% effective in younger teens

Pfizer said it plans to submit the data to the US Food and Drug Administration and the European Medicines Agency to request for emergency authorization of the vaccine.  "We will probably have it in time for the fall school year," says @ScottGottliebMD about a #COVID19 vaccine after the news from Pfizer that its vaccine has been "well-tolerated" by 12-15-year-olds $PFE pic.twitter.com/yV0eYjonjp

The FDA could authorize Pfizer's COVID-19 vaccine for 12 to 15 year olds 'in time for the fall school year,' former FDA commissioner says

Pfizer Inc. and German partner BioNTech SE said Wednesday that a Phase 3 trial of its COVID-19 vaccine in adolescents aged 12 to 15 showed 100% efficacy and robust antibody responses, an even better result than seen in an earlier study of participants 16 to 25 years old. The trial involved 2,260 adolescents in the U.S. "We plan to submit these data to FDA as a proposed amendment to our Emergency Use Authorization in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year," Pfizer Chief Executive Albert Bourla said in a statement.

Pfizer and BioNTech say COVID-19 vaccine was 100% effective in Phase 3 trial in adolescents

Eli Lilly

It looks like an uphill battle for tanezumab.

Could Pfizer's and Lilly's Long-Awaited Osteoarthritis Drug Flop?

The company said it plans to request emergency authorization in the U.S. and Europe “as soon as possible.”

Pfizer Says Its Covid-19 Vaccine Is 100% Effective In Young Teens

The Pfizer-BioNTech COVID-19 vaccine is safe and 100% effective in children as young as 12, its manufacturers have said.

Pfizer vaccine 'safe and 100% effective' in children as young as 12

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have reported Phase 3 trial data evaluating its COVID-19 vaccine BNT162b2 in 2,260 adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection. Efficacy Data: Data demonstrated 100% efficacy and substantial antibody responses, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old, and was well tolerated.

Pfizer-BioNTech's COVID-19 Vaccine Gives 100% Protection In Adolescents

Pfizer-BioNTech's COVID-19 vaccine was 100% effective at preventing COVID-19 infection in kids aged 12 to 15, the company announced Wednesday. "In participants aged 12-15 years old, [Pfizer's COVID-19 vaccine] demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier analysis and it was well tolerated," Pfizer said in a press release.

Pfizer's COVID-19 vaccine is 100% effective in 12 to 15 year olds, paving the way for approval for kids in the US and Europe

Pfizer Inc. and German partner BioNTech SE said Wednesday a Phase 3 trial of its COVID-19 vaccine in adolescents aged 12 to 15 years old showed 100% efficacy and robust antibody responses, an even better result that seen in an earlier study of participants aged 16 to 25 years old. The trial involved 2,260 adolescents in the U.S..

Pfizer and BioNTech say trial of COVID vaccine was 100% effective in Phase 3 trial of adolescents

Pfizer plans to submit the new vaccine data to the FDA "as soon as possible," CEO Albert Bourla said.

Pfizer says Covid vaccine is 100% effective in kids ages 12 to 15

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the Pfizer-BioNTech COVID-19 vaccine BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those recorded earlier in vaccinated participants aged 16 to 25 years old, and was well tolerated. These are topline results from a pivotal Phase 3 tria

Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents

A vision for the future and a cheap stock price could make this the time to buy shares.

This Is Why Pfizer Is a Great Stock to Buy Right Now

3 Reasons Pfizer Is the Best Big Pharma Stock to Buy Right Now

Innovative Industrial Properties

Scotts Miracle-Gro

Constellation Brands

Village Farms International

cbdMD Inc

You may be surprised that not all cannabis stocks are focused entirely on weed. Here are some diversified companies to consider.

News for Pfizer Stock (PFE)